Research Article
BibTex RIS Cite

Year 2023, Volume: 14 Issue: 3, 332 - 338, 10.07.2023

Aysun Işıklar Gül Başaran Ozde Melisa Celayir Gülçin Kahraman Jameela Somanje Semra Öykü Çolak Mustafa Serteser Nurdan Tozun

https://doi.org/10.31067/acusaglik.1247538

Abstract

Supporting Institution

Acıbadem Mehmet Ali Aydınlar Üniversitesi Araştırma Projeleri Ofisi

Project Number

2021-13/7

Thanks

Acıbadem Mehmet Ali Aydınlar Üniversitesi Araştırma Projeleri Ofisine

References

  • WHO (Internet). Available form: https://www.who.int/westernpacific/health-topics/detail/coronavirus? (Accessed 06 June 2021)
  • Citgez B, Yigit B, Capkinoglu E, Yetkin SG. Management of Breast Cancer during the COVID-19 Pandemic. Sisli Etfal Hastan Tip Bul. 2020;54(2):132-135. Available from: doi:10.14744/SEMB.2020.23326
  • Kuderer, NM, Choueiri TK., Shah, DP, Shyr Y, Rubinstein SM, Rivera DR et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (published correction appears in Lancet. 2020 Sep 12;396(10253):758). Lancet. 2020;395(10241):1907-1918. Available from: doi:10.1016/S0140-6736(20)31187-9
  • Fendler A, Shepherd S, Au L, Wilkinson KA, Wu M, Byrne F et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021;2:1321-1337. Available from: doi:10.1038/s43018-021-00274-w
  • Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-1773. Available from: doi:10.1056/NEJMoa2110345
  • Massarweh, A, Eliakim-Raz N, Stemmer A., Levy-Barda A, Yust-Katz S, Zer A et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(8):1133-1140. Available from: doi:10.1001/jamaoncol.2021.2155
  • Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. Available from: doi: 10.1016/j.vaccine.2021.05.063
  • Tian X, Jiang W, Zhang H, Lu X, Li L, Liu W et al. Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. Front Microbiol. 2021; 12:789374. Available from: doi:10.3389/fmicb.2021.789374
  • Lee A, Wong SY, Chai L, Lee SC, Lee MX, Muthiah MD et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632. Available from: doi:10.1136/bmj-2021-068632
  • Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2022;22(1):322-323. Available from: doi:10.1111/ajt.16775
  • Wise J. Covid-19: UK will offer third vaccine dose to severely immunosuppressed people. BMJ. 2021; 374: n2160. Available from: doi: 10.1136/bmj.n2160
  • Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin Chem Lab Med. 2021;59(8):1453-1462. Available from: doi:10.1515/cclm-2021-0214
  • National Institutes of Health. COVID-19 Treatment Guidelines. Anti-SARS-CoV-2 Antibody Products. Convalescent Plasma. Last update: October 9, 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2- antibody-products/convalescent-plasma. (Accessed 06 June 2021)
  • Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncology 2021 17:33, 4447-4456. Available from: doi:10.2217/fon-2021-0597
  • Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235-1244. Available from: doi:10.2217/fon-2021-1248
  • Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers (Basel). 2021;13(18):4621. Available from: doi:10.3390/cancers13184621
  • Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. Available from: doi:10.1016/j.esmoop.2021.100283
  • Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2. Available from: doi:10.1016/j.ccell.2021.06.002
  • Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Marco MD, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091-1098.e2. Available from: doi:10.1016/j.ccell.2021.06.009
  • Barrière, J., Carles, M., Audigier-Valette, C., Re, D., Adjtoutah, Z., Seitz-Polski, B., Gounant, V., et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. Eur J Cancer. 2022; 162:182-193. Available from: doi:10.1016/j.ejca.2021.12.011
  • Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021: e212675. Available from: doi:10.1001/jamaoncol.2021.2675

Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer

Year 2023, Volume: 14 Issue: 3, 332 - 338, 10.07.2023

Aysun Işıklar Gül Başaran Ozde Melisa Celayir Gülçin Kahraman Jameela Somanje Semra Öykü Çolak Mustafa Serteser Nurdan Tozun

https://doi.org/10.31067/acusaglik.1247538

Abstract

Background: Our study aimed to measure effectiveness of Anti-S1 RBD (receptor binding domain) IgG Antibody levels against SARS (severe acute respiratory syndrome) Cov-2 in breast cancer patients and compare them with healthy participants.
Methods: This prospective cross-sectional, single-center study was designed to evaluate Anti-S1 RBD IgG antibody levels following SARS-CoV-2 vaccination in 54 breast cancer patients and 56 healthy controls without cancer diagnosis.
Results: Anti-S1 RBD IgG antibody test was positive in 79.6% (43/54) of breast cancer patients, in 92.9% (52/56) of participants in the control group (p=0.054) and, 63.3% in breast cancer patients who were on chemotherapy+/-molecularly targeted therapy following at least two doses of vaccinations. Hybrid vaccination (use of two different types of vaccines) and more than two doses of vaccinations were associated with higher antibody titers both in patient and control groups. Median time to vaccination was 123 days (8-427) in the entire group and was significantly associated with antibody titer. Among breast cancer patients, type and frequency of vaccination, age and use of cytotoxic therapies were significantly associated with the magnitude of antibody response to SARS-CoV-2 vaccination in our study.
Conclusion: Breast cancer patients developed a lower antibody response to vaccination against COVID-19 in comparison to healthy subjects. Clinical and treatment related factors might help in tailoring future vaccination strategies for specific subsets of breast cancer patients.

Keywords

Breast cancers COVID-19 Anti-S1 RBD IgG Antibody SARS-Cov-2 vaccine.

Project Number

2021-13/7

References

  • WHO (Internet). Available form: https://www.who.int/westernpacific/health-topics/detail/coronavirus? (Accessed 06 June 2021)
  • Citgez B, Yigit B, Capkinoglu E, Yetkin SG. Management of Breast Cancer during the COVID-19 Pandemic. Sisli Etfal Hastan Tip Bul. 2020;54(2):132-135. Available from: doi:10.14744/SEMB.2020.23326
  • Kuderer, NM, Choueiri TK., Shah, DP, Shyr Y, Rubinstein SM, Rivera DR et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (published correction appears in Lancet. 2020 Sep 12;396(10253):758). Lancet. 2020;395(10241):1907-1918. Available from: doi:10.1016/S0140-6736(20)31187-9
  • Fendler A, Shepherd S, Au L, Wilkinson KA, Wu M, Byrne F et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat Cancer. 2021;2:1321-1337. Available from: doi:10.1038/s43018-021-00274-w
  • Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385(19):1761-1773. Available from: doi:10.1056/NEJMoa2110345
  • Massarweh, A, Eliakim-Raz N, Stemmer A., Levy-Barda A, Yust-Katz S, Zer A et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. 2021;7(8):1133-1140. Available from: doi:10.1001/jamaoncol.2021.2155
  • Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428. Available from: doi: 10.1016/j.vaccine.2021.05.063
  • Tian X, Jiang W, Zhang H, Lu X, Li L, Liu W et al. Persistence of the SARS-CoV-2 Antibody Response in Asymptomatic Patients in Correctional Facilities. Front Microbiol. 2021; 12:789374. Available from: doi:10.3389/fmicb.2021.789374
  • Lee A, Wong SY, Chai L, Lee SC, Lee MX, Muthiah MD et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632. Available from: doi:10.1136/bmj-2021-068632
  • Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssière L et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2022;22(1):322-323. Available from: doi:10.1111/ajt.16775
  • Wise J. Covid-19: UK will offer third vaccine dose to severely immunosuppressed people. BMJ. 2021; 374: n2160. Available from: doi: 10.1136/bmj.n2160
  • Irsara C, Egger AE, Prokop W, Nairz M, Loacker L, Sahanic S et al. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin Chem Lab Med. 2021;59(8):1453-1462. Available from: doi:10.1515/cclm-2021-0214
  • National Institutes of Health. COVID-19 Treatment Guidelines. Anti-SARS-CoV-2 Antibody Products. Convalescent Plasma. Last update: October 9, 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/anti-sars-cov-2- antibody-products/convalescent-plasma. (Accessed 06 June 2021)
  • Karacin C, Eren T, Zeynelgil E, Imamoglu GI, Altinbas M, Karadag I, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Future Oncology 2021 17:33, 4447-4456. Available from: doi:10.2217/fon-2021-0597
  • Yasin AI, Aydin SG, Sümbül B, Koral L, Şimşek M, Geredeli Ç et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022;18(10):1235-1244. Available from: doi:10.2217/fon-2021-1248
  • Linardou H, Spanakis N, Koliou GA, Christopoulou A, Karageorgopoulou S, Alevra N et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. Cancers (Basel). 2021;13(18):4621. Available from: doi:10.3390/cancers13184621
  • Grinshpun A, Rottenberg Y, Ben-Dov IZ, Djian E, Wolf DG, Kadouri L. Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment. ESMO Open. 2021;6(6):100283. Available from: doi:10.1016/j.esmoop.2021.100283
  • Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081-1090.e2. Available from: doi:10.1016/j.ccell.2021.06.002
  • Addeo A, Shah PK, Bordry N, Hudson RD, Albracht B, Marco MD, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39(8):1091-1098.e2. Available from: doi:10.1016/j.ccell.2021.06.009
  • Barrière, J., Carles, M., Audigier-Valette, C., Re, D., Adjtoutah, Z., Seitz-Polski, B., Gounant, V., et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article. Eur J Cancer. 2022; 162:182-193. Available from: doi:10.1016/j.ejca.2021.12.011
  • Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021: e212675. Available from: doi:10.1001/jamaoncol.2021.2675
There are 21 citations in total.

Details

Primary Language English
Subjects Biochemistry and Cell Biology (Other), Clinical Sciences, Oncology and Carcinogenesis
Journal Section Research Article
Authors

Aysun Işıklar 0000-0003-2690-3067

Gül Başaran 0000-0002-0775-6180

Ozde Melisa Celayir 0000-0002-8562-7085

Gülçin Kahraman 0000-0003-1235-5389

Jameela Somanje 0000-0002-6181-6113

Semra Öykü Çolak 0000-0002-8609-9747

Mustafa Serteser 0000-0001-7868-7613

Nurdan Tozun 0000-0001-6487-2551

Project Number 2021-13/7
Early Pub Date June 14, 2023
Publication Date July 10, 2023
Submission Date February 9, 2023
Published in Issue Year 2023Volume: 14 Issue: 3

Cite

EndNote Işıklar A, Başaran G, Celayir OM, Kahraman G, Somanje J, Çolak SÖ, Serteser M, Tozun N (July 1, 2023) Serologic Response to SARS-CoV-2 Vaccine in Patients with Breast Cancer. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 14 3 332–338.
 Download Cover Image